ACCESS Newswire·Jun 15, 2026, 8:00 AM ET

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Telomir Pharmaceuticals announced peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy showing Telomir-Zn normalized insulin resistance in a diet-induced zebrafish model of Type 2 diabetes.
Treatment with Telomir-Zn for 14 days reduced HOMA-IR values from approximately 10-12 in untreated animals to approximately 3, indicating significant restoration of insulin sensitivity.
Dose-dependent improvements included reduced fasting blood glucose levels, improved glucose clearance during oral glucose tolerance testing, & lower fasting insulin concentrations.
The study validates Telomir-Zn's mechanism of modulating intracellular metal homeostasis to address oxidative stress & mitochondrial dysfunction common to both metabolic disease & cancer.
Telomir Pharmaceuticals recently received FDA Investigational New Drug clearance for its Phase 1/2 clinical trial (TELO-001) in patients with advanced or metastatic triple-negative breast cancer.
Company executives highlighted this as the second peer-reviewed publication on Telomir-Zn in 2026, supporting the potential of their metal-homeostasis platform across multiple disease models.